KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
12.97
+0.38 (3.02%)
Aug 14, 2025, 11:42 AM - Market open
KalVista Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
270
Market Cap
645.41M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
KALV News
- 2 days ago - Metagenomi Appoints Laurence Reid, PhD to its Board of Directors - GlobeNewsWire
- 3 days ago - KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union - Business Wire
- 10 days ago - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 20 days ago - KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks - Business Wire
- 4 weeks ago - KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire
- 5 weeks ago - KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results - Business Wire
- 5 weeks ago - KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning - Seeking Alpha
- 5 weeks ago - US FDA approves KalVista Pharma's swelling disorder drug - Reuters